RESUMEN
Herein we report a 30-year-old man presenting with fevers, headaches and weight loss. On admission he was disorientated and demonstrated no focal signs of neurological deficit. Magnetic resonance imaging revealed a large area of abnormal bone marrow signal centred within the clivus with extension into the sphenoid sinus and signs of associated basal meningitis. A sphenoid sinus biopsy was performed and proved non diagnostic. The patient was treated empirically with antitubercular therapy (ATT). Lumbar puncture provided cerebrospinal fluid from which Mycobacterium tuberculosis (MTB) was isolated 35 days later. His clinical course was complicated by development of communicating hydrocephalus requiring placement of a ventriculoperitoneal shunt and addition of thalidomide. The patient was discharged following a ten-week admission with complete resolution of symptoms and remains well two years later.
RESUMEN
BACKGROUND: In England, choice of hepatitis C therapy is determined by national contracts that change with time, facilitating comparisons between different regimens. England has a diverse population with hepatitis C including large proportions of uncommon viral genotypes. AIM: To evaluate efficacy of directly acting anti-viral treatments for hepatitis C in England using real-world data from the national treatment registry. METHODS: Sustained virological response (SVR) rates 12 weeks after treatment completion for patients treated between 2014 and August 2018 who attended for SVR tests were analysed in univariate subgroups using Chi-squared tests. Multivariate models were constructed with clinically relevant variables to determine predictors of SVR and evaluate the impact of treatment regimens. RESULTS: SVR data were available on 14,603 treated patients. The overall SVR rate was 95.59% [95% CI 95.25%-95.91%]. Multivariable regression modelling in patients with genotype 1 infection showed that the odds of SVR with elbasvir/grazoprevir were higher than for those treated with sofosbuvir/ledipasvir (OR 1.891, 95% CI 1.072-3.336, P = 0.028). For genotype 3, we found no significant difference between any of the treatment regimens. Patients who completed at least one third of the planned treatment duration achieved SVR rates in excess of 80%. CONCLUSIONS: All of the currently licensed hepatitis C direct-acting anti-viral regimens had similar efficacy (>95%) in an unselected population. Noncompletion of planned treatment duration still resulted in over 80% SVR rates provided that more than one third of treatment was completed.
Asunto(s)
Antivirales/uso terapéutico , Hepatitis C/tratamiento farmacológico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anilidas/uso terapéutico , Bencimidazoles/uso terapéutico , Benzofuranos/uso terapéutico , Carbamatos/uso terapéutico , Ciclopropanos , Combinación de Medicamentos , Inglaterra , Femenino , Fluorenos/uso terapéutico , Humanos , Imidazoles/uso terapéutico , Lactamas Macrocíclicas , Compuestos Macrocíclicos/uso terapéutico , Masculino , Persona de Mediana Edad , Prolina/análogos & derivados , Quinoxalinas/uso terapéutico , Sistema de Registros , Ribavirina/uso terapéutico , Sofosbuvir , Sulfonamidas , Respuesta Virológica Sostenida , Uridina Monofosfato/análogos & derivados , Uridina Monofosfato/uso terapéutico , Valina , Adulto JovenRESUMEN
BACKGROUND: Eosinophilic oesophagitis (EoE) is a chronic, inflammatory condition of the oesophagus, characterised by intermittent dysphagia, food bolus obstruction (FBO) and histologically proven, eosinophil-mediated inflammation. EoE is identified in up to 50% of FBO presentations. OBJECTIVE: To evaluate the management of patients presenting with FBO to our centre against current clinical guidelines. DESIGN: A retrospective analysis of acute FBO was performed between January 2008 and August 2014. Patients were identified using the ICD 10 code T18.1, 'foreign body in oesophagus' in their electronic discharge document. Data were collected on admitting specialty, previous FBO, endoscopy findings, biopsy sites and findings, eosinophil count and diagnosis of EoE. RESULTS: 310 acute episodes of FBO were included in the final study cohort. 202 (65.2%) flexible oesophagogastroduodenoscopies (OGDs) were performed, with 50 (34.5%) of those occurring in those admitted under ENT (n=145), versus 28 (93.3%) and 124 (91.9%) in general medicine (n=30) and surgery (n=135), respectively. 80 (39.6%) had oesophageal biopsies taken, and 21 novel diagnoses of EoE were made (26.3% biopsy-proven rate). Five (23.8%) of the novel diagnoses had a formal eosinophil count included in the histopathology report, and eight (38.1%) had up to three previous OGDs that had not diagnosed their condition of EoE. CONCLUSION: Our study highlights wide variation in adherence to the guidelines for the management of FBO depending on admitting specialty. We advocate an FBO protocol involving single specialty management, flexible OGD, ≥6 biopsies from the upper and lower oesophagus, and standardisation of oesophageal biopsy reports with a formal eosinophil count.